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Background: Certain advanced chronic conditions (heart failure, chronic lung disease) are associated with high
mortality. Nevertheless, most of the time, patients with these conditions are not given the same level of attention
or palliative care as those with cancer.
The objective of this study was to assess mortality and its association with other variables in a cohort of complex
multimorbid patients with heart failure and/or lung disease from two consecutive telemonitoring studies.
Methods: This multicentre longitudinal study was conducted between 2010 and 2015. We included 83 patients (27
without telemonitoring) with heart failure and/or lung disease with > 1 hospital admission in the previous year and
great difficulties leaving home or were housebound. The following variables were indicators of their complex
clinical condition: old age (mean: 81 years), comorbidity (Charlson Comorbidity Index score ≥ 2: 86.2 %), both
conditions concurrently (54.2 %) and home oxygen therapy (52 %).
We assessed mortality (rate, cause and place of death) and its association with: age, sex, telemonitoring, functional
status (Barthel score), quality of life (EQ-5D visual analogue scale), number of medications, and all-cause and condition-
specific (due to conditions prompting inclusion) admissions during the previous year. Uni- and bivariate analysis and
logistic regression were performed, considering p < 0.05 significant.
Results: A total of 61 patients died within 5 years, representing 31.2 %/year (95 % CI: 23–40.1 %), considering the
overall follow-up (sum of individual follow-up days). Of these, 81 % of deaths (95 % CI: 69.1–89–1 %) were due to the
condition prompting inclusion, and 83.3 % (95 % CI: 72–90.7 %) died in hospital (median: 8.5 days).
Mortality was lower among those under telemonitoring (p = 0.027), and with fewer condition-specific admissions the
previous year (p = 0.006); the latter also showed the strongest association in the multivariate analysis (Exp(B) = 6.115).
Conclusions: Complex patients with multimorbidity had a high mortality rate, generally dying due to the
condition for which they had been included, and in hospital (83.3 %). New approaches for managing such
patients should be considered, introducing palliative care as required, and using more comprehensive
predictors of mortality (functional status and quality of life), together with those related to the illness itself
(previous admissions, progression and symptoms).
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When we consider end-of-life patients under palliative
care, there is a tendency to think of patients with ter-
minal cancer; indeed, in practice, palliative care is
mainly focused on this type of patient. However,
given current demographic changes, with progressive
population ageing and longer survival, advanced
chronic illnesses are becoming the leading cause of
patients requiring end-of-life care. At the same time,
we should consider that the palliative care model in-
volves starting to take certain measures well before
advanced stages of illness leading towards death.
Ideally, palliative care should overlap with curative
treatments in cases of poor prognosis, this being con-
sidered a more comprehensive patient-centred ap-
proach, taking into account not only clinical but also
psychosocial and existential needs. Its objective is to
avoid discomfort and suffering in the wider sense, im-
proving quality of life as much as possible and avoid-
ing unnecessary treatments.
The two best examples of this situation are chronic
obstructive pulmonary disease (COPD) and heart failure
(HF), due to their prevalence and the percentage of pa-
tients in final and irreversible stages. However, as we will
discuss below, it is difficult to define the terminal state,
and the most common scenario is that such patients are
not given palliative care, but rather continue on care
pathways designed for earlier stages of the illness.
COPD is characterised by progressive deterioration
over time, with persistence of symptoms, episodes of ex-
acerbation, and frequent hospitalisation, as well as a high
mortality rate in the most advanced patients, of around
30 % per year [1–3]. Despite this, relatively few patients
receive standard palliative care [4], only 5 % according
to some authors [5], and they even have limited access
to general healthcare in these advanced stages of the dis-
ease, when they spend most of their time at home. It is
not easy to establish when their shortened life expect-
ancy makes such patients candidates for receiving
mainly palliative care. However, there are specific tools,
such as the Body mass index, airflow Obstruction, Dys-
pnoea, and Exercise (BODE) index, and certain factors
such as the degree of deterioration of pulmonary func-
tion, frequency of exacerbations and hospital admissions,
and progression of respiratory failure (dyspnoea, need
for continuous oxygen therapy, etc.) that can guide us
on when to initiate this type of care [6–8].
HF shares many characteristics with COPD in terms
of progression and prognosis. There is also progressive
deterioration, in advanced stages of the illness, it is asso-
ciated with frequent exacerbations and hospitalisation,
and in the end stages death is often predictable. How-
ever, it is not uncommon that patients receive aggressive
therapies until death despite their poor prognosis [9]. Asfor COPD, there are tools to assess who might benefit
from palliative care, such as the CARING (Cancer,
Admissions ≥ 2, Residence in a nursing home, Intensive
care unit admission with multiorgan failure, ≥ 2 Non-
cancer hospice Guidelines) criteria and criteria based on
National Hospice Organization guidelines, for assessing
shortened life expectancy, although such an assessment
can also be based on recurrent and evolving signs and
symptoms [9]. In cases of severe HF, the mortality rate is
also around 30 % per year.
Despite it being common for older adults to have one
or more chronic conditions at advance stages, these
conditions coexisting and interacting with the individ-
ual’s functional and overall health status, very few
studies have addressed mortality and palliative care
by considering multimorbidity in a comprehensive
manner.
The consecutive studies TELBIL and TELBIL-A con-
sisted of a clinical trial and an implementation evaluation,
respectively [10–12], of primary care-based telemonitoring
of chronic patients. These studies have had two main
characteristics; on the one hand, the importance of pri-
mary care in the management of the telemonitoring and
follow-up of patients, and on the other, the multimorbidity
and complexity of the patients (with chronic lung disease
and/or HF). For this reason, they represent an opportunity
for analysing mortality, its characteristics and implica-
tions, in a comprehensive manner with a focus on
multimorbidity.
The objective of this study was to describe the
characteristics of mortality and its association with
other relevant variables, in a cohort of complex
multimorbid patients with HF and/or chronic lung
disease (in most cases, COPD) from the TELBIL and
TELBIL-A studies, regardless of whether they had
been under telemonitoring.
Methods
Study design and location
Multicentre descriptive longitudinal study of the cohort
of all the patients who participated in two consecutive
and overlapping telemonitoring studies (TELBIL and
TELBIL-A) from February 2010 to February 2015, the
overall period during which patients were followed up.
Figure 1 shows the flow of patients through the study.
The research was conducted in the urban Bilbao-
Basurto Integrated Healthcare Organisation. This
organisation is composed of a reference hospital
(Basurto University Hospital) and 25 health centres
(with a combined staff of 230 general practitioners,
320 nurses and 72 paediatricians), and a catchment
population of 382,000 people, of whom over 20 %
were ≥ 65 years old. Patients in the area can also be
referred to Santa Marina hospital, a subacute hospital,
Fig. 1 Study design and patient flow
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bidity with their own palliative care unit.
Study patients
In the analysis, we included all the patients from both
studies (TELBIL and TELBIL-A, n = 83) whether they
had been under telemonitoring (56) or not (27) during
the study period; 18 patients had been included in both
studies. The patients were all complex patients with
multimorbidity, as a result of the inclusion criteria
applied, especially the requirement that they had great
difficulties leaving their home or were effectively
housebound, this implying very poor baseline functional
status. Table 1 summarises the most relevant characteris-
tics that define this complexity.
Inclusion criteria
In both projects, we included:
– adult patients with HF and/or chronic lung disease
(COPD, chronic asthma, or others)– with two or more admissions to hospital in the
previous year (at least one of these being due to the
condition that prompted inclusion in the study)
– who had great difficulties leaving their home or
were effectively housebound, meaning that they
were usually provided care at home.
Exclusion criteria
We excluded patients in long-term care, with a life expect-
ancy of less than 6 months due to an illness other than
those related to their inclusion in the study, with potential
barriers to continuous follow-up, or social/family circum-
stances that might have hindered their participation.
Ethical approval
Both studies (TELBIL and TELBIL-A) were approved by
the corresponding clinical research ethics committee
(that of Basurto University Hospital) and the primary
care research committee. Before patients were included
in the study, they or their relatives provided written in-
formed consent.
Table 1 Main characteristics characterising the complexity of the patients included in the TELBIL and TELBIL-A studies
Variable Valuea
Age, years 81.3 (IQR: 77.1 to 85.4)
Condition prompting inclusion Heart failure 21.7 %; chronic lung disease 24.1 %;
both concurrently 54.2 %
Severity of the COPDb based on FEV1c 82.6 % severe or very severe
Charlson Comorbidity Index score≥ 2c 86.2 %
Number of different regular medications 11 (IQR: 9 to 14)
Continuous home oxygen therapyc 51.7 %
BADLd, Barthel Index score on inclusion 75 (IQR: 50 to 90)
HRQoLe, EQ-5D VAS scoree on inclusion 40 (IQR: 30 to 60)
Lack of social support (specific questionnaire)c 17.2 %
Number of all-cause admissions the year before inclusion 3 (IQR: 2 to 4)
Number of condition-specific admissionsf the year before inclusion 2 (IQR: 1 to 3)
Number of home visits by a doctor and/or nurse the year before inclusionc 22.5 (IQR: 12 to 31)
aResults are expressed as percentages, if they are qualitative variables, or mean and interquartile range (IQR), if they are quantitative
bCOPD: chronic obstructive pulmonary disease
cData for the sample of 59 patients from the TELBIL study (randomised clinical trial); the rest refer to all 83 patients
dBADL: basic activities of daily living
eHRQoL: health-related quality of life; EQ-5D VAS: EuroQol EQ-5D visual analogue scale
fOnly hospital admissions due to the conditions (heart failure and/or chronic lung disease) that prompted inclusion are considered
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The primary variable in this study was mortality, includ-
ing its rate and other characteristics:
– cause of death, and whether it was due to a condition
that prompted inclusion (condition-specific mortality),
– place of death (in hospital or at home) and duration
of hospital stay until death, in such cases.
We also collected data on:
– patient age in years on inclusion in the study and sex
– health conditions for which patients were included
(HF, chronic lung disease, or both)
– whether they were under telemonitoring during
some of the follow-up period
– assessment of ability to perform basic activities of
daily living (BADL), the Barthel Index score [13] on
inclusion
– assessment of health-related quality of life (HRQoL)
(EuroQol EQ-5D) [14] on inclusion
– number of medications taken on a regular basis on
inclusion
– number of admissions to hospital in the year prior
to inclusion, considering both all-cause and
condition-specific admissions.
Estimation of the power of the study
We included all patients who participated in the two
previous studies (TELBIL and TELBIL-A), and hence,
sample size calculations were carried out prior to thismortality analysis, with estimates being based on hos-
pital admissions. However, considering a prevalence of
300 patients with these characteristics in the catchment
population (based on the lists used for the initial recruit-
ment), and the 83 patients included, and assuming a
mortality of 30 % and a margin of error of 5 %, the
power of the study would be 80 %.Source of data
Data were collected from the primary care electronic
health records and hospital electronic discharge records,
as well as from the databases created for each of the
TELBIL studies.Data analysis
We carried out a univariate analysis of the variables,
using the mean and the standard deviation, or the me-
dian and the interquartile range (IQR), as measures of
central tendency and dispersion, as appropriate, depend-
ing on whether data were normally distributed. We esti-
mated population values, inferential statistics, for the
most important values (rate and place of death). To as-
sess the association between mortality and the rest of
variables studied, bivariate analysis was performed with
Student’s t test or Mann–Whitney U test (in the case of
non-normally distributed or ordinal data) for the quanti-
tative variables, and the chi-squared test for qualitative
variables. The analysis was completed with a multivariate
binary logistic regression analysis, using the “Enter”
method, considering whether a patient had died during
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All the analyses were carried out using the IBM SPSS
Statistics for Windows version, 20. The level of statistical
significance was set at p < 0.05.
Results
We included 83 patients of whom 35 were female
(42.2 %) and the median age of the sample on inclusion
was 81.6 years (IQR: 77.1 to 85.4; range 51 to 95). The
conditions prompting inclusion were HF in 21.7 % of pa-
tients (18), and chronic lung disease in 24.1 % (20) (the
majority of these patients, 78.6 %, having COPD), while
52.4 % (45) had both diseases at the same time. A total
of 56 patients were telemonitored (67.5 %), some for the
full 5 years of follow-up, the other 27 patients being in
the control group in the TELBIL study.
During the study period, 61 patients died (73.5 %,
95 % CI 63–82 %). Considering an overall follow-up of
190 patients/year, based on a cumulative total of
69,380 days of follow-up for the 83 patients, this corre-
sponds to a mortality rate of 31.2 % patients/year (95 %
CI: 23–40.1 %).
Regarding causes of death, 81 % (95 % CI 69.1 %–
89.1 %) died due to the condition that had prompted
their inclusion (condition-specific mortality). Overall,Table 2 Association between whether or not patients from the TELBIL










Age in years on inclusion, median (IQR)
Barthel index score (0 to 100)
EQ-5D VAS scorec (0 to 100)
Number of regular medications
Number of all-cause admissions the year before inclusion
Number of condition-specific (heart or lung-related) admissions the year befo
aFor the qualitative variables (having been telemonitored or not, inclusion condition
hypothesis testing. For the others, qualitative variables (expressed as medians and
as the data were not normally distributed or the sample size was small
bIn complementary analysis to assess the influence of the length of follow-up, the diffe
(mean of 851 vs. 805 days respectively) was not found to be significant (p = 0.712)
cEQ-5D VAS: EuroQol EQ-5D visual analogue scale
in bold variables con statistical significance <0.0534.5 % died due to a heart condition (all of them due to
HF) and 48.3 % due to a respiratory condition (of these,
57.1 % dying due to respiratory infection or pneumonia,
39.3 % due to exacerbation of lung disease or respiratory
failure without infection, and 1 patient due to an associ-
ated lung tumour); while in 3 cases it was not possible
to determine the cause of death. Ten patients died at
home (16.7 %, 95 % CI: 9.3–28 %), and 50 in hospital
(83.3 %, 95 % CI: 72–90.7 %), 4 of these dying in the
emergency department, while in 1 patient it was not
possible to determine the place of death. Out of the 46
patients who died during admission, the median length
of hospital stay was 8.5 days (IQR: 4 to 15.3, with a max-
imum value of 35 days).
Table 2 shows the relationship between whether pa-
tients died and the rest of the study variables. We found
the mortality rate was significantly lower among those
who had been under telemonitoring, and significantly
higher among those with more condition-specific admis-
sions in the year prior to inclusion.
We carried out multivariate logistic regression ana-
lysis, considering whether the patient died as the
dependent variable, and the rest of the variables as the
independent variables. The omnibus chi-square value
was <0.0001 (indicating that the model explains the







37 (60.7 %) 19 (86.4 %)
24 (39.3 %) 3 (13.6 %)
0.888
14 (22.9 %) 6 (27.3 %)
13 (21.3 %) 5 (22.7 %)
34 (55.8 %) 11 (50 %)
0.889
26 (42.6 %) 9 (40.9 %)
35 (57.4 %) 13 (59.1 %)
81 (78 to 87) 81.3 (71 to 84) 0.192
70 (40 to 87.5) 87.5 (60 to 100) 0.120
40 (25 to 60) 50 (37.5 to 65) 0.148
11 (9 to 13) 12 (10 to 14) 0.219
3 (2 to 4) 3 (1 to 4) 0.384
re inclusion 2 (2 to 3) 2 (1 to 2) 0.006
and sex, expressed as frequencies and percentages), we used chi-square for
interquartile ranges [IQRs]), we used the non-parametric Mann–Whitney U test,
rence in follow-up time between those who were and were not telemonitored
Table 3 Statistics for the independent variables from the logistic regression analysis, using the Enter method, considering whether a










.971 2.789 1 .095 .197
Inclusion condition .248 .470 .278 1 .598 1.281
Sex –.228 .802 .081 1 .776 .796
Age in years on inclusion .107 .053 3.990 1 .046 1.113
Barthel Index score (BADL)a –.041 .020 4.179 1 .041 .959
EQ-5D VAS score (HRQoL)b –.049 .024 4.185 1 .041 .952
Number of regular medications .030 .124 .060 1 .807 1.031
Number of all-cause admissions the year before inclusion –
1.278
.424 9.085 1 .003 .278
Number of condition-specific admissionsc the year before
inclusion
1.811 .537 11.356 1 .001 6.115
Constant –
1.551
4.615 .113 1 .737 .212
aBADL: basic activities of daily living
bEQ-5D VAS: EuroQol EQ-5D visual analogue scale; HRQoL: health-related quality of life
cOnly hospital admissions due to the conditions (heart failure and/or chronic lung disease) that prompted inclusion are considered
in bold variables con statistical significance <0.05
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explanatory. Table 3 summarises the results of this ana-
lysis, using the Enter method. We found that the follow-
ing variables were significant for explaining the
dependent variable: age, Barthel Index score, and EQ-5D
visual analogue scale score on inclusion; and all-cause (a
protective effect) and condition-specific admissions. The
variable most closely related to dying was the number of
condition-specific admissions in the previous year.Discussion
The baseline characteristics of the patients included in
the TELBIL and TELBIL-A studies, including concurrent
health problems with 50 % having both HF and lung
disease, reflect the high level of comorbidity and com-
plexity of these patients. This gave us the opportunity to
conduct research considering their complexity and over-
all characteristics, rather than focusing on a specific
pathology or health condition, which has previously
been the usual approach.
The TELBIL telemonitoring strategy has shown to de-
crease the number of admissions and length of hospital
stay, with good cost-effectiveness ratios, and good ac-
ceptance among patients and their families as well as
health professionals [11, 12]. This was achieved in pa-
tients who in many cases had a poor health status and
short life expectancy. Building on the previous TELBIL
studies, we have carried out a specific analysis of mortal-
ity, and the results can contribute to the identification ofnew strategies to help improve the wellbeing of these
kinds of patients and their families.
Our patients had a high mortality rate, estimated to be
31.2 %/year, which is consistent with figures reported by
other authors [1–3, 7, 15, 16]. In our case, 73.5 % of pa-
tients died within the 5-year study period, although few
patients had been followed-up for the entire period
(open inclusion). This result underlines the high com-
plexity and advanced stage of illness in our patients, as
the rate is somewhat higher than that observed by other
authors over 5 full years of follow-up of patients with
advanced COPD, mortality over the follow-up period
being around 70 % [3, 6].
The majority of deaths were due to health problems
that prompted inclusion in the study (HF and lung dis-
ease), condition-specific mortality, as could be expected.
In patients whose inclusion was based on them having
HF, all cases of death due to heart-related causes were
associated with decompensation of the HF, sometimes
triggered by other factors. In those whose inclusion was
based on them having lung disease, nearly all deaths
were due to exacerbation of the disease, in some cases
associated with a respiratory infection. That is, our
patients died due to the health conditions that had
prompted their inclusion and to a limited range of asso-
ciated causes. This specificity and association of death
with patients’ primary health problems has also been
described by other authors [17–19].
Taking into account the aforementioned factors
(complexity and severity of patients’ condition, high
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of death), the most striking finding in our study was
that the majority of patients (83.3 %) died in hospital
rather than at home. This pattern has also been re-
ported by other authors [20], and is despite the fact
that their own home may be the most comfortable
and appropriate place to die, and according to the lit-
erature, the place where a high percentage of this
type of patient say they would prefer to die [7, 21,
22]. Based on the review of the clinical records (not
supported with specific analysis), we appreciated that
during the hospitalization in which the patients died,
treatment and management did not differ generally
from others the patients had previously except, in
many cases, in the palliative care once near death.
This seems to indicate that we continue to focus on
the illness and have not taken on board the concept
of palliative care, that we do not have the resources
to make it easier for these patients stay in their
homes in the end stages of their illness, or more
likely, a combination of both. Further, we should also
consider the length of hospital stays during which pa-
tients died, with a median of 8.5 days and more
than15 days in 25 % of cases, recognising that this
period is likely to have been highly burdensome given
the characteristics of the conditions and commonly
associated symptoms (e.g., severe dyspnoea).
The number of condition-specific admissions (at-
tributable to the conditions that prompted inclusion)
in the previous year was found to be strongly associ-
ated with mortality in both the bivariate and multi-
variate models. As we have mentioned earlier,
hospitalisation is frequent in the advanced stages of
these illnesses, and behaves as a predictive factor. In
the multivariate analysis, other variables that were
found to be associated with mortality were functional
status (Barthel Index score) and perceived quality of
life (EQ-5D visual analogue scale score), and consid-
eration of these two factors is likely to be key to the
proper management of these patients on the basis of
their multimorbidity and complexity rather than spe-
cific illnesses. In fact, functional status was found to
be the single most important factor in the prediction
of in-hospital death, above other measures of illness
severity [9]. Further, the new technologies for sup-
porting the provision of care (telemonitoring) have
also been found to have an effect, especially in redu-
cing hospitalisation [11, 12], and tending to delay
death, although the latter finding was not conclusive,
largely due to the small sample size. The result ob-
tained in terms of all-cause hospital admissions in
the previous year was unclear, in that it seemed to
indicate, according to the logistic regression, that the
more all-cause admissions, the lower the mortality.This finding must be interpreted with care, however,
as it is inconsistent with the bivariate analysis, in
which admissions in the previous year was strongly
positively associated with mortality, helping to ex-
plain death in a more rational way, and further this
admission rate is probably linked to other variables
studied.
The community setting, in particular primary care, is
an important environment in which to monitor and
manage this type of complex patient, given its accessible
location and the approachability of the health care pro-
viders, frequency of contacts, and efficiency. It is import-
ant to have sufficient professional training and
resources, including nurse case managers, who, although
they seem to have limited effect on readmissions, do
seem to have a positive impact on patient quality of life
and satisfaction with care provided [23], and palliative
care teams [4]. As well as ensuring good coordination
between the different levels of care and services [7, 24],
patients should be involved in their own care, progres-
sion and prognosis of their conditions, and their prefer-
ences about care should be considered, steps which do
not seem to be taken in most cases [22, 25]. We con-
sider there is a progressive improvement in the commu-
nity health site in all these aspects, including the
support by caregivers and relatives, although there is still
much to be done, with the main target of giving the best
and most comfortable assistance.
We believe that is important to start to consolidate
the management of these patients in a different way:
– considering functional status, history of
hospitalisation, HRQoL and comorbidity, to have a
better idea of the overall health status and life
expectancy of complex multimorbid patients and
specifically those with HF or chronic lung disease
– assessing life expectancy, to determine the type of
care that is appropriate, and starting palliative care
when required, even overlapping with curative care
at earlier stages of illness
– considering the use or the need to make available
specific complementary healthcare resources and
support to facilitate better management of these
patients, with appropriate coordination between
levels of care and involving patients, and their
relatives and caregivers, in patient care.
The fact that we selected highly-complex patients
for this research, particularly by applying the inclu-
sion criterion of having great difficulties leaving home
or being effectively housebound, may hinder the gen-
eralisation of our findings to other less extreme situa-
tions. However, we believe that this limitation is
relatively unimportant for the interpretation and
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when comparing our findings with those of other
studies.
It is necessary to continue searching for strategies
to help characterise terminal status in non-cancer
patients, and assessing new strategies for managing
such patients.
Conclusions
Complex multimorbid patients with HF or lung disease
often have a short life expectancy, and despite this, in most
cases, no consideration is given to providing adequate care
based on a palliative care model. As a consequence, most
such patients die in hospital, many after relatively long
stays, which are likely to have been highly burdensome, far
from the social and family environment that would be more
suitable (in particular, their own home).
There is need for another approach to this situation
and the management of these patients, based on pre-
dictive factors, such as functional status, that are
more comprehensive than those associated with their
specific pathologies or health conditions, and consid-
ering quality of life, as well as a coordinated and
comprehensive healthcare system with sufficient re-
sources, with the community/primary care setting
playing a leading role.
Nevertheless, a history of hospitalisation due to the
primary illness, and intensity and progression of asso-
ciated symptoms, signs and test results may help to
assess the life expectancy of these patients.
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